key: cord-0683347-w1z4o257
authors: Pal, Rimesh; Bhadada, Sanjay K
title: Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?
date: 2020-04-10
journal: Diabetes Res Clin Pract
DOI: 10.1016/j.diabres.2020.108146
sha: f72471977c1c83a8985b482d8890212828fc8e2c
doc_id: 683347
cord_uid: w1z4o257

nan

Ever since its outbreak in December 2019, novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to more than 200 nations, affecting over 509,000 individuals and inflicting over 23,000 fatalities globally (1) . Although the overall mortality rate is low, ranging from 1.4%-7.2%, people with diabetes mellitus (DM) tend to have more severe disease, acute respiratory distress syndrome and increased fatality (2, 3) . Of the 1099 confirmed COVID-19 patients reported from China, 173 had severe disease; DM was more prevalent in those with severe disease (16.2%) as compared to those with non-severe disease (5.7%) (2) . In addition, DM has been reported to be associated with poor prognosis in other viral infections, notably seasonal influenza, pandemic influenza A H1N1 (2009), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Proposed mechanisms for this apparent association between COVID-19 and DM include impaired innate immune system in people with DM. In addition, angiotensin-converting enzyme inhibitors (ACEi) and angiotensinreceptor blockers (ARBs), used so widely in people with DM have been implicated as a connecting link between COVID-19 and DM. ACEi/ARBs leads to upregulation of angiotensin-converting enzyme 2 (ACE2), a type 1 integral membrane glycoprotein that is constitutively expressed in the lungs, heart, intestine, kidney and vascular endothelium. SARS-CoV-2 utilizes ACE2 as a receptor for entry into host pneumocytes, hence, upregulation of ACE2 by ACEi/ARBs might explain the severe and fatal consequences of COVID-19 (3).

Considering the high-risk, persons with DM should take extra precautions amid COVID-19 pandemic. Strict social distancing and proper hang hygiene should be the norm. Good glycemic control should be of utmost importance as it has been shown to boost the innate immune system. Although it would be wise to stick to the ongoing therapy or intensify the same, physicians may however consider reviewing the prescription.

Insulin is a safe choice under most circumstances and remains the sole therapy for people with type 1 diabetes mellitus and can be considered as a superior alternative in people with type 2 diabetes mellitus (T2DM) having poor glycemic control. Although no direct effect on ACE2 is reported, insulin treatment has been shown to attenuate renal ADAM-17 (a disintegrin and metalloproteinase-17) expression in diabetic Akita mice (4). In normal physiology, ADAM-17 cleaves ACE2, thereby inactivating the enzyme. Whether the same phenomenon is replicated in human pneumocytes is not known. Metformin and sulfonylureas exhibits no interaction with either ACE2 or ADAM-17 and can be safely continued. On the contrary, pioglitazone has been shown to upregulate ACE2 in insulin-sensitive tissues in rats and reduce ADAM-17 activity in human skeletal muscles (3, 5) . Similarly, liraglutide, a glucagon-like peptide 1 (GLP1) analogue, increases cardiac and pulmonary ACE2 expression in Type 1 diabetic rats (6) . Data also supports promotion of ACE2 activity by sodium-glucose transporter 2 inhibitors (SGLT2i); this has been proposed as a plausible mechanism of renoprotection with this class of drugs (7). Can be considered as a third-line add on drug in patients with poor glycemic control

Coronavirus disease 2019 (COVID-19) Situation Report -67

Clinical Characteristics of Coronavirus Disease 2019 in China

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice

Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, doubleblind, placebo-controlled, mechanistic study

Activation of the GLP-1 Receptor by Liraglutide Increases ACE2

Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

COVID-19 and Diabetes: can DPP4 inhibition play a role?

Effect of early addition of hydroxychloroquine in type 2 diabetic patients inadequately controlled on metformin and sulfonylurea combination therapy

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Table 1. Table showing commonly prescribed anti-diabetic drugs and concerns regarding their use during COVID-19 pandemic

Thus, any anti-diabetic drug that upregulates ACE2 directly or indirectly by inhibition of ADAM-17 (a disintegrin and metalloproteinase-17, an enzyme that cleaves and inactivates ACE2) is theoretically expected to promote SARS-CoV-2 infection

Sodium-glucose transporter 2; DPP4: Dipeptidyl peptidase 4; DPP4 H/M : Transgenic diabetic mice expressing human DPP4